Published online before print June 4, 2007, doi: 10.1161/HYPERTENSIONAHA.107.090803
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2007;50:37.)
© 2007 American Heart Association, Inc.
Editorial Commentaries |
Does 20-Hydroxyeicosatetraenoic Acid Contribute to Sex Differences in Cardiovascular Risk by Increasing Oxidative Stress?
From the Department of Physiology, Medical College of Wisconsin, Milwaukee.
Correspondence to Richard J. Roman, Department of Physiology and Kidney Disease Center, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail rroman{at}mcw.edu
Previous studies have indicated that there are large sex differences in the incidence of hypertension, and the role of androgens in enhancing the risk of cardiovascular disease is well recognized.1,2 However, the mechanisms by which androgens increase blood pressure are poorly understood. Recent studies have demonstrated that androgen-sensitive forms of hypertension are associated with increased production of 20-hydroxyeicosatetranoic acid (20-HETE) in the kidney and the vasculature.3 However, the role of 20-HETE in this form of hypertension has not been established, because this pathway has both prohypertensive and antihypertensive actions.4 At the level of the renal tubule, upregulation of the formation of 20-HETE inhibits sodium transport and opposes the development of hypertension, whereas in the vasculature, 20-HETE is a potent vasoconstrictor that promotes hypertension.
The study of Singh et al5 in the current issue explores the role of 20-HETE in the development of endothelial dysfunction and hypertension in rats chronically treated with dihydrotestosterone. The results indicate that that the expression cytochrome P450 4A protein and the production of 20 HETE increase in renal arteries of rats treated with dihydrotestosterone. The increase in vascular 20-HETE production is because of upregulation of the expression of the cytochrome P450 4A8 isoform. The development of hypertension in these studies was associated with the development of endothelial dysfunction, as reflected by an impaired vasodilator response to acetylcholine, increased expression of the gp-91 and gp-47 phox subunits of reduced nicotinamide-adenine dinucleotide phosphate oxidase, and increased superoxide production by the vasculature. More importantly, this study is the first to establish a cause-and-effect relationship among elevated vascular production of 20-HETE, endothelial dysfunction, and hypertension. To do this, these authors demonstrated that chronic treatment of the rats with a selective inhibitor of the synthesis of 20-HETE prevents the increases in vascular production of superoxide, endothelial dysfunction, and hypertension in rats treated with dihydrotestosterone. These studies strongly implicate elevated vascular production of 20-HETE as an essential mediator of endothelial dysfunction and the elevated vascular tone in androgen-induced hypertension.
The results of the present study have a number of implications. Previous studies indicated that 20-HETE plays an important role in the regulation of renal tubular and vascular function,4 but the role of this system in mediating oxidative stress and endothelial function has only been recognized recently when Wang et al6 reported that upregulation of vascular cytochrome P450 4A2 expression using an adenoviral vector increased the production of 20-HETE and impaired endothelial function. Subsequent studies have explored several mechanisms by which 20-HETE alters the response to endothelium-dependent vasodilators.7,8 These pathways are summarized in the Figure. It now appears that the vascular production of 20-HETE is elevated in spontaneous hypertensive rats and in angiotensin II– and androgen-induced models of hypertension.3,5,9,10 This is probably secondary to upregulation of the expression of cytochrome P450 4A isoforms by androgens, angiotensin II, sympathetic tone (catecholamines), and endothelin.4 Increased production of 20-HETE in the vasculature is associated with endothelial dysfunction and increased vascular tone, which contributes to the development of the elevated blood pressure in these models of hypertension. At least 3 different pathways play a role in this response. The study by Singh et al5 indicates that 20-HETE increases the vascular expression of subunits of reduced nicotinamide-adenine dinucleotide phosphate oxidase that produce superoxide. Other studies indicate that 20-HETE affects the association of endothelial NO synthase with heat shock protein 90, leading to diminished formation of NO and increased formation of superoxide.6,7 Finally, Guo et al8 reported recently that 20-HETE directly increases the formation of superoxide by endothelial cells. All of these changes in the vasculature diminish the bioavailability of NO, leading to endothelial dysfunction and hypertension.
|
As with any groundbreaking study, this article raises a number of questions that will have to be addressed in future studies. It is well known that endothelial dysfunction is a common feature associated with the development of nearly all forms of hypertension and diabetes. Thus, it will be important to determine whether upregulation of the vascular production of 20-HETE is a common pathway in the development of endothelial dysfunction or if this is limited to androgen-induced hypertension. Another intriguing question is whether upregulation of vascular of 20-HETE production contributes to the elevated risk of heart attack and stroke in male hypertensive patients. This question is of great clinical interest in light of recent findings that inhibitors of 20-HETE reduce cerebral vasospasm after subarachnoid hemorrhage11 and reduce infarct size after transient ischemia and reperfusion of the heart12 and the brain.13 Another question is the relative importance of changes in the renal versus vascular production of 20-HETE in androgen-induced and other forms of hypertension. For example, the present study indicates that 20-HETE production is increased in the vasculature and that this promotes vasoconstriction and the development of hypertension. However, one has to wonder whether infusion of dihydrotestosterone also induces the production of 20-HETE in the kidney, which would promote natriuresis. It will be important to determine in the future whether this reflects differential regulation of the cytochrome P450 4A isoforms in kidney versus the vasculature and to what extent this can help explain why inhibitors of 20-HETE formation lower blood pressure in some models of hypertension (spontaneously hypertensive rats,14,15 angiotensin II–induced,10 and androgen-induced5), but a deficiency in the renal formation of 20-HETE is associated with the development of salt-sensitive hypertension in normotensive Sprague–Dawley16 and in Dahl salt-sensitive rats.17
Clearly, more work is needed to address these issues, but it now appears that elevated vascular production of 20-HETE contributes to endothelial dysfunction and the development of hypertension and cardiovascular disease in spontaneously hypertensive rats and in angiotensin II– and androgen-induced models of this disease. Sex differences in the expression of cytochrome P450 4A isoforms and the production of 20-HETE in the vasculature may also underlie some of the cardiovascular protection afforded premenopausal women.
 |
Acknowledgments |
|---|
Sources of Funding
This work was supported in part by National Institutes of Health grants HL36279 and HL29587.
Disclosures
None.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
 Top References |
|---|
1. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001; 37: 1199–1208.
2. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocrine Rev. 2003; 24: 313–340.
3. Nakagawa K, Marji JS, Schwartzman ML, Waterman MR, Capdevila JH. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol. 2003; 284: R1055–R1062.
4. Roman RJ. P450 metabolites of arachidonic acid in the control of cardiovascular function. Physiological Rev. 2002; 82: 131–185.
5. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension. 2007; 50: 123–129.
6. Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS, Hintze TH, Abraham NG, Nasjletti A, Laniado-Schwartzman M. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res. 2006; 98: 962–969.
7. Chen Y, Medhora MM, Falck JR, Pritchard KA, Jacobs ER. Mechanisms of activation of eNOS by 20-hydroxyeicosatetraenoic acid and VEGF in bovine pulmonary artery endothelial cells. Am J Physiol. 2006; 291: L369–L377.
8. Guo AM, Arbab AS, Falck JR, Chen P, Edwards PA, Roman RJ, Scicli AG. Activation of VEGF through ROS mediates 20-HETE-induced endothelial cell proliferation. J Pharmacol Exp Ther. 2007; 321: 18–27.
9. Omata K, Abraham NG, Escalante B, Schwartzman ML. Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am J Physiol. 1992; 262: F8–F16.[Medline] [Order article via Infotrieve]
10. Alonso-Galicia M, Maier KG, Greene AS, Cowley AW Jr, Roman RJ. Role of 20-hydroxyeicosatet-raenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol. 2002; 283: R60–R68.
11. Roman RJ, Renic M, Dunn KM, Takeuchi K, Hacein-Bey L. Evidence that 20-HETE contributes to the development of acute and delayed cerebral vasospasm. Neurol Res. 2006; 28: 738–749.[CrossRef][Medline] [Order article via Infotrieve]
12. Nithipatikom K, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ. Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol. 2006; 290: H500–H505.
13. Omura T, Tanaka Y, Miyata N, Koizumi C, Sakurai T, Fukasawa M, Hachiuma K, Minagawa T, Susumu T, Yoshida S, Nakaike S, Okuyama S, Harder DR, Roman RJ. Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke. 2006; 37: 1307–1313.
14. Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, Laniado-Schwartzman M. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol. 2001; 280: R255–R261.
15. Xu F, Straub WO, Pak W, Su P, Maier KG, Yu M, Roman RJ, Ortiz De Montellano PR, Kroetz DL. Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. Am J Physiol. 2002; 283: R710–R720.
16. Hoagland KM, Flasch AK, Roman RJ. Blockade of renal 20-HETE formation promotes salt-sensitive hypertension in rats. Hypertension. 2003; 42: 669–673.
17. Roman RJ, Hoagland KM, Lopez B, Kwitek AE, Garrett MR, Rapp JP, Lazar J, Jacob HJ, Sarkis A. Characterization of blood pressure and renal function in chromosome 5 congenic strains of Dahl S rats. Am J Physiol. 2006; 290: F1463–F1471.
Related Article:
Hypertension 2007 50: 123-129.
This article has been cited by other articles:
 |
|
 |
|
  D. Gebremedhin, K. Yamaura, and D. R. Harder Role of 20-HETE in the hypoxia-induced activation of Ca2+-activated K+ channel currents in rat cerebral arterial muscle cells Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H107 - H120. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||